Clinical Trial

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Protocol Amendment History 1 change
notable Trial sites expanded: 133 -> 136 locations 2026-07-21
Trial Details
NCT Number NCT07222332
Lead Sponsor Eli Lilly and Company
Conditions Diabetes Mellitus, Type 1
Enrollment 300 participants
Start Date 2026-02-05
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-20